News

newspapers


  • Theravectys and the Institut Pasteur extend the Joint-Lab
    Paris, October 25th 2019

THERAVECTYS & THE INSTITUT PASTEUR EXTEND THE JOINT-LAB

To capitalize on their licensing agreement and boost synergies THERAVECTYS and the INSTITUT PASTEUR reaffirm their collaborative JOINT-LAB based on the Lentiviral Vectors Technology.

PARIS, October, 25. 2019 – THERAVECTYS, a vaccine company that designs and develops safe and highly efficient T-cell vaccines based on a proprietary lentiviral vector platform, announces the consolidation of its long-standing collaboration with the Institut Pasteur through the extension of the R&D Joint-Lab.

Since its incorporation in 2005, through a global and exclusive license granted by the Institut Pasteur to its spin-off created by Dr Pierre Charneau, TheraVectys has controlled, or benefited from, 100% of the rights on lentiviral vectors vaccines. The Joint-Lab between TheraVectys and Institut Pasteur designated under “IPTV” allows an effective synergy between TheraVectys and, the Molecular Virology and Vectorology Unit of the Pasteur Institute, while giving access to numerous technological platforms available in the Pasteur Institute.

“We are honored to pursue this unique collaboration with the prestigious Pasteur Institute” says Jean Chalopin CEO. These first two years of collaboration demonstrate the potential of this platform in terms of value creation and the efficiency of this plural ecosystem. This extension validates this innovative model to leverage at best R&D progress and maintain a sustained innovative pipeline while positioning the Lentiviral Vectors as a breakthrough therapy against cancers and major infectious diseases”.

“The IPTV joint Laboratory is unique in the Pasteur Institute (IP). After few months of installation and training of staff, we quickly arrived at a very satisfactory level of scientific production. The quality of the work performed by the IPTV laboratory will lead in the coming months to a series of publications and patent deposits in the infectious field as well as in anti-tumor applications.” says Dr. Pierre Charneau, Head of the Joint-Lab.

The Joint-Lab Agreement has been extended for two years since June 7th, 2019, with a collaborative pipeline of 14 projects i.e 5 additional indications compared to the initial perimeter at IPTV creation date in 2017.

ABOUT THERAVECTYS

THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer inventor Dr. Pierre Charneau, as a spin-off of the Institut Pasteur, TheraVectys leverages a unique proprietary platform to deliver remarkably safe and highly efficient T-cell vaccines as a response to critical unmet medical needs. THERAVECTYS’ technology and worldwide license domain has an almost unlimited number of applications in infectious diseases, virally-induced cancers and cancers, and is probably a major silent revolution in vaccination since the discovery of the vaccine against rabies by Louis Pasteur. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our PoC-validated vaccine-candidates to clinical trials and to market.

ABOUT THE INSTITUT PASTEUR AND THE INSTITUT PASTEUR INTERNATIONAL NETWORK:

The Institut Pasteur, a private foundation with officially recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research with a network of 33 institutes worldwide. In the pursuit of its mission to prevent and fight against diseases in France and throughout the world, the Institut Pasteur operates in four main areas: scientific and medical research, public health and health monitoring, teaching, and business development and technology transfer.

More than 2,500 people work on its Paris campus. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology. Its 130 units also focus their research on certain cancers, genetic and neurodegenerative diseases, genomics and developmental biology. This research aims to expand our knowledge of living organisms in a bid to lay the foundation for new prevention strategies and novel therapeutics. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS.

With a portfolio of 350 patent families, 24 new spin-off companies, and over 170 license/sublicense and research agreements in the fields of diagnostics, vaccines and therapeutics, the Institut Pasteur plays a major role in technology transfer activities that directly benefit patients and generate significant resources to further support its research activities.

  • NOVASEP and THERAVECTYS Enter Into a New License Agreement on DNA Flap Technology for GMP Manufacturing of Lentiviral Vectors
    Paris and Lyon, April 18th 2019

NOVASEP and THERAVECTYS Enter Into a New License Agreement on DNA Flap Technology for GMP Manufacturing of Lentiviral Vectors

This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines.

PARIS and LYON, France, April 18, 2019 /PRNewswire/ -- Novasep, a leading supplier of services and technologies for the life sciences industry, and Theravectys, a discovery & clinical development biotech company, today announced the signing of a license agreement allowing Novasep to use Institut Pasteur's DNA Flap Technology to produce GMP-grade lentiviral vectors for clinical use in all therapeutic applications including gene therapy, cell therapy, immunotherapy and vaccination, for any customer, worldwide. Financial terms were not disclosed.

Theravectys holds a license from the Institut Pasteur, covering the production of lentiviral vectors and their use for vaccination applications.

“The lentiviral vector DNA Flap Technology has a huge potential for a new generation of therapeutic vaccines and immunotherapies, including the recently approved CAR-T cell immunotherapies to treat cancer," said Jean Bléhaut, President of Novasep's Manufacturing Solutions Business Unit. "This license agreement enables Novasep to secure the right to produce such lentiviral vectors for our customers worldwide." He added: "It is an important step of our RISE-2 strategy, aimed at doubling our profitability by 2022, following 2 major investments at our Seneffe, Belgium site: "Senrise-IV", our recently inaugurated, commercial viral vector manufacturing plant and "Senefill", our new commercial fill & finish facility, which will be commissioned in 2019."

The DNA Flap technology is derived from the genome of a lentivirus - and consists of a DNA sequence, including the cPPT and CTS cis-active sequences, that actively enables the import of any gene into a cell nucleus. Lentiviral vectors are thus employed to deliver genes of therapeutic interest to non-replicating cells, hence their efficacy in gene therapy and in T-cell engineering (CAR-T).

With more than 300 drugs under development, around 200 drugs in clinical trials, and 2 recently approved products, the production pipeline for viral vectors for chimeric antigen receptor (CAR) T cell immunotherapy is very promising.

ABOUT THERAVECTYS

Theravectys, a privately-owned biotech company, translates 20+ years of research on lentiviral vectors into a paradigm shift in vaccine development. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Institut Pasteur, Theravectys leverages its proprietary platform and worldwide exclusive rights to Institut Pasteur's intellectual property to deliver safe and efficient T-cell vaccines in oncology and infectious diseases. Theravectys' on-going first-in-human Phase I/IIa clinical trial for its therapeutic vaccine candidate against HIV is projected to close in early 2019.

ABOUT NOVASEP

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.

  • THERAVECTYS and SHANGHAI JINWEI BIOTECHNOLOGY Entered Into Development and License Agreements
    Paris, 2019

THERAVECTYS and SHANGHAI JINWEI BIOTECHNOLOGY Entered Into Development and License Agreements

Theravectys SA (“Theravectys”) and Shanghai Jinwei Biotechnology Co., Ltd. (“Jinwei”) announced they have entered into two license agreements - one in 2017 for the development, manufacture and commercialization of therapeutic vaccines for chronic hepatitis B infection (“HBV license agreement”), and another in 2018 for the development, manufacture and commercialization of personalized therapeutic vaccines for cancer (“cancer license agreement”). em>

Under the terms of the HBV license agreement, Theravectys granted Jinwei an exclusive license to certain intellectual property rights owned, controlled or licensed by TVS relating to lentiviral vector technologies. Jinwei will have exclusive rights to develop, manufacture and commercialize therapeutic vaccines for chronic hepatitis B infection in Great China. In addition, Jinwei will have non-exclusive right to manufacture, formulate and package GMP batches of lentiviral vectors or lentiviral vector-based vaccines for clinical trials as a service for third parties.

Under the terms of the cancer license agreement, Theravectys granted Jinwei an exclusive license to certain intellectual property rights owned, controlled or licensed by TVS relating to lentiviral vector technologies. Jinwei Bio will have exclusive rights to develop, manufacture and commercialize personalized therapeutic vaccines for cancer in Great China.

For each license agreement, Theravectys received an upfront payment and is eligible to receive development and regulatory milestone payments and royalties based on product sales.

ABOUT THERAVECTYS

Theravectys SA, a privately-owned vaccine company, translates more than 20 years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology and immunotherapies. Founded by pioneer inventor Dr. Pierre Charneau as a spin-off of the Institute Pasteur, Theravectys leverages a unique proprietary platform to deliver safe and highly efficient lentiviral vaccines and immunotherapies that induce strong antigen-specific T cell responses, addressing critical unmet medical needs. Theravectys’ technology and worldwide license domain has an almost unlimited number of applications in infectious diseases and oncology, and can be considered as the major silent revolution in vaccination since the discovery of the vaccine against rabies by Louis Pasteur. Theravectys’ purpose is to profoundly transform global health.

ABOUT SHANGHAI JINWEI BIOTECHNOLOGY

Shanghai Jinwei Biotechnology Co., Ltd. (“Jinwei”) is a biotechnology company dedicated to pursuing innovative technology to develop cures for people with serious and life-threatening diseases. Jinwei has obtained exclusive license of multiple patents and other intellectual property owned by the Pasteur Institute and Theravectys for the manufacturing and supply of lentiviral vectors and for the development, manufacture and commercialization of therapeutic products based on lentiviral vectors. Jinwei has established partnership with renowned institutions including Huashan Hospital to develop leading edge therapies for various cancers such as liver and prostate cancers as well as infectious diseases such as HBV and Tuberculosis. In addition, Jinwei has built a GMP production site in Shanghai to provide safe and reliable lentiviral vector products for CAR-T and other biopharmaceuticals, helping to translate early stage research into commercially viable therapies.